A phase 1/2 study evaluating brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma after failure of frontline therapy - Regional Cancer Care Associates LLC

Clinical Trials

A phase 1/2 study evaluating brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma after failure of frontline therapy

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Seattle Genetics
Protocol Number
SGN35-025
Cancer Diagnosis
To Learn More Call
201-510-0910